ArticleEClinicalMedicine2026
Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In advanced-stage classic Hodgkin lymphoma (cHL), risk-adapted therapeutic strategies have proven to be safe and effective, although long term efficacy data are lacking. Furthermore, some concern persists about the risk of late occurrence of second primary malignancies (SPM) or cardiovascular events (CVE) in survivors. Methods: HD0607 is a phase-2 multicenter prospective clinical trial enrolling stage IIB-IV patients with untreated cHL. All subjects started treatment with 2 ABVD cycles and subsequently underwent an interim PET (PET-2). PET-2 positive patients [Deauville score (DS) 4-5] switched to BEACOPP escalated/baseline (4 + 4 cycles), while PET-2 negative patients (DS ≤ 3) were treated with 4 more ABVD cycles. Patients with a large nodal mass (LNM, defined as ≥5 cm in diameter) at baseline and both PET-2 and end-of-chemotherapy (EoT) PET negative scans were randomly allocated to receive consolidation radiotherapy (cRT) or no further therapy (NFT). This clinical trial has been registered in the European Union Drug Regulating Authorities Clinical Trials Database under the EudraCT number 2007-007168-94 and is publicly available on the EU Clinical Trials Register. Findings: Out of 782 enrolled subjects, 630 (81%) had a negative while 150 (19%) a positive PET-2. After a median follow-up of 11 years (IQR 7-13 years), 102/630 patients with a negative PET-2 (16.2%) and 57/150 (38.0%) with a positive PET-2 progressed or relapsed. The 10-years PFS and OS were 83% and 96% vs. 58% and 85% (p < 0.0001) for PET-2 negative and PET-2 positive patients, respectively. Patients randomized to NFT did not have an increased risk of relapse or death (PFS HR 0.67, 95%CI 0.31-1.43; OS HR 0.49, 95% CI 0.09-2.68). During the follow-up 28 (3.6%) and 16 (2.1%) patients developed a SPM and CVE, respectively. Interpretation: After more than a decade of follow-up the HD0607 trial confirmed: i) the long-term predictive value of PET-2; ii) the persistent and sustained remission rate of PET-2 negative patients; iii) no PFS benefit consolidation RT over a non-FDG avid LNM; iv) the cumulative low incidence of SPM and CVE in the enrolled patients. Funding: This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), IG n.2013 to AG, by Associazione Italiana Lotta alla Leucemia (AIL) sezione di Bergamo and by a Research Grant of Cassa di Risparmio di Cuneo. Progetti di Rilevanza Nazionale PRIN PNRR (P2022PSMX4), STARS UNIPD 2023 to AV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.